52288-3 MML:AEA:sch PTO/SB/08A (08-03) Approved for use through 07/31/2008, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb Complete if Known Substitute for form 1449/PTO Application Number Not yet assigned February 8, 2006 Filing Date INFORMATION DISCLOSURE First Named Inventor Suzanne Chamberland et STATEMENT BY APPLICANT Art Unit Not yet assigned (Use as many sheets as necessary) Examiner Name Not yet assigned Attorney Docket Number 4810-73194-01 Sheet 1 Ωf U.S. PATENT DOCUMENTS Page, Columns, Lines. **Document Number** Name of Patentee or Publication Examiner Cite Date Applicant of Cited Document Where Relevant Initials No. Passages or Relevant MM-DD-YYY Number-Kind code 2 (if know Figures Appear 03-04-2004 Neurosearch A/S **A1** US-2004/0043987 US-2004/0131628 A1 07-08-2004 Bratzler, Robert L. et al. A2 National Science Council (TW) 11-01-2004 **A3** US-6,479,499 07-03-2003 Bayer Corporation A4 US-2003-0125344 Bankston, Q. et al. 11-27-2003 **A5** US-2003/0220357 10-31-2002 Chanchal, Sadhu et al. **A6** US-2002161014 A1 Pamkcu, R.; Pjazza, G. 02-28-2002 'A7 US-2002/0025968 ZAR 08-06-2002 Sepracor Inc. US-6,429,311 A9 US-2001/0018518 08-30-2001 Gao, Yun 10-23-2001 Pfizer, Inc. A10 US-6,306,864 10-23-2001 Xerox Corporation A11 US-6,380,204 02-06-2001 Sepracor Inc. A12 US-6,184,377 B1 07-25-1995 Ono Pharmaceutical Co. Ltd. A13 US-5,436,233 Ono Pharmaceutical Co. Ltd A14 US-5,439,895 08-08-1995 **A15** 07-20-1976 Diamond Shamrock US-3,970,648 08-03-1976 Diamond Shamrock A16 US-3,973,021 08-20-1976 Diamond Shamrock A17 US-3,974,277 Norwich 11-24-1970 A18 US-3,542,784 07-06-1967 A19 Norwich US-3,324,122

Examiner Initials *	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			Figures Appear	T <sup>8</sup>
MI	B1	WO 2005/014585 A1	Feb. 17/05	Ulysses Pharmaceuticals Products Inc.		
1	B2	WO 2004/004658 A2	Jan. 15/04	Point Therapeutics, Inc.		$oxed{\Box}$
	В3	WO 2003/091224 AI	Nov 6/03	Nippon Shinyaku Co. Ltd.		
TNA	B4	WO 01/81346 A3	Nov. 1/01	ICOS Corp.		TC

Examiner Signature	1 Chris	Date Considered	5/	ul	07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds codes of USPTO patent Documents at <a href="https://www.upsto.gov">www.upsto.gov</a> or MPEP 901.04 The Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a checkmark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/567,660

Hoder	the Panen	work Reduction Act of 1995, no persons are	required to r	esnand	U.S. Patent and Tra	demark Office: U.S	PTO/SB/08B ough 07/31/2008. OMB 063 DEPARTMENT OF COMI Italins a valid OMB control of	51-0031 MERCE
		form 1449/PTO	Toquires to t	1		omplete if Kn		$\overline{}$
300	SINUIB IOI	10111 1446/- 10		Appli	ication Number	Not yet assign	gned	
INFORMATION DISCLOSURE			Filing Date February 8, 2006		2006	008		
				First Named Inventor Suzanne Chamberland et al.		amberland et al.		
S	ГАТЕ	MENT BY APPLICAN	IT	Art U	Jnit	Not yet accid	ined 16-24	
	(U	se as many sheets as necessary)		Exan	niner Name	<u>Not yet assig</u>	T. TRU	WZ
Sheet 2		of 3		Attorr	ney Docket Number	4810-73194-		
		Foreign P	atent Do	cume	nts (continued			
Examiner	Cite	Foreign Patent Document	Public		Name of P		Pages, Columns,	Τ <sup>6</sup>
Initials *	No. 1	1	Date MM-0	-	Applicant of Ci	ted Document	Lines, Where Relevant Passages	
	:	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	YYY				or Relevant Figures Appear	
TN1 .	B5	WO 9834111 A1	Aug. 6	/98	Trega Bioscien	ces Inc. (US)		
1	B6	WO 9834115 A1	Aug. 6/	/98	Trega Bioscien	ces Inc. (US)		
V	B7	DE 2,140,280	Feb. 17	7/72	Chemische Fat Heyden GmbH			П
t	В8	GB 1,168,430	Oct. 22	2/69	The Norwich Pl			
	B9	BE 672504	Mar. 16	3/66	The Norwich Pl	harmacal		<del>  </del>
771		DE 072304	IVIA.	3/00	Company			
Examiner	Cite	NON PATER Include name of the author (in			RE DOCUMENT		ppropriate), title of	
Initials *	No. 1	the item (book, magazine, jour number(s), r			posium, catalog, nd /or country wh		ges), volume-issue	T <sup>2</sup>
TNT~	€1	Burch, Homer A., "Nitrofuryl h derivatives" Journal of Medicin	eterocycl nal Chem	es, IV istry (	.4-Amino-2-(5-r 1966), 9(3), 408	nitro-2-furyl) qu 3-10 ,		
IV	/C2	Cohen, Samuel M. et al., "Cor nitrofurans in rats" Journal of	he Natioi	nal Ca	ancer Institute (1	1976), 57(2), 2	77-82 🌲	
	C3	Desos, Patrice et al. "Structure						
		Bearing Different Acidic Funct phosphonic Acid, a New Poter						
<b>\</b> \	/	Neuroprotective Properties" Jo						ŀ
V	C4	Gupta, K. "Addressing Antibio						
	C5	Hour, Mann-Jen "6-Alkylaming						
Related Compunds: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization"  Journal of Medicinal Chemistry (2000) 43(23) 4479-4487.								
Examiner	<del></del>		·			Date		
Signature Considered 5/11/07								
considered. In Applicant's un This collection to process) and gathering, prejamount of time Trademark Office.	nclude copy nique citati of informa application paring, and e you requi fice, P.O. B	ference considered, whether or not citation is y of this form with next communication to ap ion designation number (optional). Applica tion is required by 37 CFR 1.98. The inform n. Confidentiality is governed by 35 U.S.C. I submitting the completed application form re to complete this form and/or suggestions sox 1450, Alexandria, VA 22313-1450. DO Ints, P.O. Box 1450, Alexandria, VA 22313	plicant. Int is to place nation is requingled and 37 Cto the USPTC for reducing	a check ired to co CFR 1.14 D. Time this bur	kmark here if English obtain or retain a bene 4. This collection is e will vary depending u	language Translation of the public which stimated to take 2 happen the individual of the Chief Information of the Chief I	on is attached. ch is to file (and by the USF ours to complete, including case. Any comments on the on Officer, U.S. Patent and	<b>РТО</b>
	If yo	ou need assistance in completing the f	orm, call 1-	800-P	TO-9199 (1-800-78	36-9199) and sele	ect option 2.	

10/567,660

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

s	substitute for form	1449/PTO		Complete if Known		
•				Application Number	Not yet assigned	
	NEODMA	TION	DISCLOSURE	Filing Date	February 8, 2006	
_				First Named Inventor	Suzanne Chamberland et al.	
	STATEME	NT B	Y APPLICANT	Art Unit	Nekyerassignee /624	
	(Use as	many she	ets as necessary)	Examiner Name	Not vet assigned T. TRUONS	
Sheet	3	of	3	Attorney Docket Number	4810-73194-01	

		NON PATENT LITERATURE DOCUMENTS (continued)	Τ
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city and /or country where published.	T²
M	Æ6	Jiang, Jack B. et al. "Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization" <i>Journal of Medicinal Chemistry</i> (1990) 33(6) 1721-28 •	ū
7	,C7	Molina, Enrique et al., "Designing Antibacterial Compounds through a Topological Substructural Approach" Journal of Chemical Information and Computer Sciences (2004), 44(2), 515-521 •	
٢	C8	Moskalenko, N. Yu et al., "4-Amino-2-styrylquinazolines,- a new class of antiprotozoal drugs" Khimiko-Farmatsevticheskii Zhumal (1986), 20(4), 437-46	
t	Œ9	Nicolle, L.E. "Urninary Tract Infection: Traditional Pharmacologic Therapies" (2003) 49(2) 111-128	
7	C10	Ogawa, Nobuo et al. "Synthesis and histamine H2-antagonist activity of 4-quinzolinione derivatives" Chemical & Pharmaceutical Bulletin (1988) 36(8) 2955-67	
L	211	Van Natta, J.P. et al., "Determination of untreated whole-milk effects on in vitro antibacterial activity" Applied Microbiology (1970), 19(2), 220-23.	
V	Æ12	Yakhontov, L.N. et al., "Synthesis and Study of Biological Activity of Substituted 4-Amino-2- Styrylquinazolines" Khimiko-Farmatsevticheskii Zhumal (1975) 9(11) 12-18	
	<b>©13</b>	Zhikhareva, G.P. et al., "Synthesis and Anti-Inflammatory Activity of Substituted 2-styryl-4-(δ-diethylamino-α-methylbutylamino)-6-amitro and 2-styryl-4-(δ-diethylamino-α-methylbutylamino)-6-aminoquinazolines" Khimiko-Farmatsevticheskii Zhumal (1980) 14(2), 45-49	0
MU	/C14	Zhikhareva, G.P. et al., "Synthesis and Antiviral Activity of Substituted 4-(5-diethylamino-a-methylbutylamino)-2-styrylqulnazolines" Khimiko-Farmatsevticheskii Zhurnal (1978) 12(11) 44-48	

Examiner Signature	Mon	Date Considered	5/11/07

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete duding gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

13	y
INFORMATION	DISCLOSURE STATEMENT
	' APPLICANT

Attorney Docket Number	4810-73194-01
Application Number	10/567,660
Filing Date	February 8, 2006
First Named Inventor	Chamberland
Art Unit	1624
Examiner Name	Tamthom Ngo Truong

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
TNT	~	Supplementary European Search Report for Application No. EP 04 76 1630, 2 pages, dated November 11, 2006.
TMT		Moskalenko, N. Yu, et al., "4-Amino—styrylquinazolines – a new class of antiprotozoal drugs," <i>Database Caplus [Online] Chemical Abstracts Service</i> , XP002404560 retrieved from STN, Database accession no. 1987:32975, 2 pages.
TMT	✓	Khimiko-Farmatsevticheskii Zhurnal, 20(4), 437-446, Coden: KHFZAN; ISSN: 0023-1134, 1986, XP002917813. (See cite No. C8 on Information Disclosure Statement dated June 20, 2006.),
	L	
		·
	' · · · ·	
	· ·	
		•

EXAMINER SIGNATURE:	DATE CONSIDERED: 5	/11/07
	L	I '

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.